Targeting Protein Kinase C in Glioblastoma Treatment

Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor and is associated with a poor prognosis. Despite the use of combined treatment approaches, recurrence is almost inevitable and survival longer than 14 or 15 months after diagnosis is low. It is therefore necessary to identify...

Descripción completa

Detalles Bibliográficos
Autores principales: Geribaldi-Doldán, Noelia, Hervás-Corpión, Irati, Gómez-Oliva, Ricardo, Domínguez-García, Samuel, Ruiz, Félix A., Iglesias-Lozano, Irene, Carrascal, Livia, Pardillo-Díaz, Ricardo, Gil-Salú, José L., Nunez-Abades, Pedro, Valor, Luis M., Castro, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067000/
https://www.ncbi.nlm.nih.gov/pubmed/33916593
http://dx.doi.org/10.3390/biomedicines9040381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067000/
https://www.ncbi.nlm.nih.gov/pubmed/33916593
http://dx.doi.org/10.3390/biomedicines9040381

Ejemplares similares